The Goldman Sachs Group, Inc. 13D and 13G filings for Rhythm Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-10 5:30 pm Sale |
2024-12-31 | 13G | Rhythm Pharmaceuticals, Inc. RYTM |
GOLDMAN SACHS GROUP INC GS |
1,818,932 3.000% |
-2,072,088 (-53.25%) |
Filing |
| 2024-11-12 5:23 pm Sale |
2024-09-30 | 13G | Rhythm Pharmaceuticals, Inc. RYTM |
GOLDMAN SACHS GROUP INC GS |
3,891,020 6.400% |
-1,107,741 (-22.16%) |
Filing |
| 2024-02-05 5:34 pm Sale |
2023-12-29 | 13G | Rhythm Pharmaceuticals, Inc. RYTM |
GOLDMAN SACHS GROUP INC GS |
4,998,761 8.500% |
-202,499 (-3.89%) |
Filing |
| 2023-02-07 6:12 pm Purchase |
2022-12-30 | 13G | Rhythm Pharmaceuticals, Inc. RYTM |
GOLDMAN SACHS GROUP INC GS |
5,201,260 9.200% |
2,143,701 (+70.11%) |
Filing |
| 2022-01-24 10:32 am Purchase |
2021-12-31 | 13G | Rhythm Pharmaceuticals, Inc. RYTM |
GOLDMAN SACHS GROUP INC GS |
3,057,559 6.100% |
3,057,559 (New Position) |
Filing |